Patents by Inventor Kwang-Ok Lee
Kwang-Ok Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240128557Abstract: An energy storage module includes: a plurality of battery cells arranged in a first direction such that long side surfaces of adjacent ones of the battery cells face one another; a plurality of insulation spacers, at least one of the insulation spacers being between each adjacent pair of the battery cells, each of the insulation spacers including a heat-insulating first sheet and a plurality of flame-retardant second sheets respectively adhered to opposite surfaces of the first sheet by an adhesion member; a cover member including an internal receiving space configured to accommodate the battery cells and the insulation spacers; a top plate coupled to the cover member, the top plate including ducts respectively corresponding to vents of the battery cells and having fire extinguishing agent openings respectively corresponding to the insulation spacers; a top cover coupled to the top plate and having discharge openings respectively corresponding to the ducts; and an extinguisher sheet between the top cover andType: ApplicationFiled: October 14, 2023Publication date: April 18, 2024Inventors: Jin Taek KIM, Eun Ok KWAK, Jang Hoon KIM, Jin Bhum YUN, Jong Yeol WOO, Kwang Deuk LEE, Woo Sung CHOI
-
Patent number: 11958897Abstract: The present invention relates to an anti-VAMP2 antibody that inhibits SNARE complex and uses thereof, and more specifically, the present invention relates to an anti-VAMP2 antibody or antigen-binding fragments thereof comprising heavy and light chain CDRs of a specific sequence. The anti-VAMP2 antibody is expected to be useful for improving or treating skin wrinkles by inhibiting SNARE complex formation.Type: GrantFiled: August 14, 2019Date of Patent: April 16, 2024Assignee: HAUUL BIOInventors: Hee-Jun Na, Yun-Suk Lee, Je-Ok Yoo, Kwang-Soon Lee, Kang Seung Lee, Seung Je Min
-
Publication number: 20240113382Abstract: An energy storage module includes: a cover member accommodating a plurality of battery cells in an internal receiving space, each of the battery cells including a vent; a top plate coupled to a top of the cover member and including a duct corresponding to the vent of at least one of the battery cells; a top cover coupled to a top of the top plate and having an exhaust area corresponding to the duct, the exhaust area having a plurality of discharge openings, the top cover including a protrusion protruding from a bottom surface of the top cover, the protrusion extending around a periphery of the exhaust area and around a distal end of the duct; and an extinguisher sheet between the top cover and the top plate, the extinguisher sheet being configured to emit a fire extinguishing agent at a reference temperature.Type: ApplicationFiled: December 6, 2023Publication date: April 4, 2024Inventors: Jin Taek KIM, Eun Ok KWAK, Jang Hoon KIM, Jin Bhum YUN, Jong Yeol WOO, Kwang Deuk LEE, Woo Sung CHOI
-
Publication number: 20240092141Abstract: An air conditioning device for a vehicle includes: a housing having an inside divided into an inflow space, a heat exchange space, and an outflow space, which are straightly arranged, and having a plurality of discharge ports, which communicates with an interior, at the inflow space; a blowing unit disposed at the inflow space of the housing and configured to blow air; a heat exchange unit disposed at the heat exchange space of the housing and configured to adjust a temperature of conditioned air by exchanging heat with air; and an opening-closing door disposed at the outflow space of the housing and configured to open and close the plurality of discharge ports such that conditioned air at an adjusted temperature selectively flows to the plurality of discharge ports. The air conditioning device adjusts the temperature of conditioned air for respective modes and reduces a flow resistance of air.Type: ApplicationFiled: March 8, 2023Publication date: March 21, 2024Applicants: HYUNDAI MOTOR COMPANY, KIA CORPORATION, DOOWON CLIMATE CONTROL CO., LTD.Inventors: Kwang Ok Han, Young Tae Song, Yong Chul Kim, Gee Young Shin, Su Yeon Kang, Jae Sik Choi, Dae Hee Lee, Byeong Moo Jang, Ung Hwi Kim, Jae Won Cha, Won Jun Joung, Byung Guk An
-
Publication number: 20230095520Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, wherein the pharmaceutical composition comprises a thiazole derivative or a pharmaceutically acceptable salt thereof. Specifically, the present invention relates to a pharmaceutical composition that selectively inhibits the activity of CDK7 to reduce side effects, and treats and prevents cancer by inhibiting the proliferation of all cancer cells, rather than being limited to specific cancer cells.Type: ApplicationFiled: March 12, 2021Publication date: March 30, 2023Inventors: Kwang Ok Lee, Ja Kyung Yoo, Jun Hee Lee, Mijung Lee, Kangwoo Lee, Ji Eun Min
-
Patent number: 11254645Abstract: The present disclosure relates to a method for preparing tolimidone on large scale with maintaining high purity and uniform particle size distribution, and more specifically, a method suitable for preparing tolimidone on industrially large scale by using tetrabutyl ammonium bromide catalyst and recrystallization in ethanol, which can prepare highly pure tolimidone in a time shorter than prior arts while maintaining water content and particle size distribution constantly.Type: GrantFiled: January 11, 2018Date of Patent: February 22, 2022Assignee: BUKWANG PHARMACEUTICAL CO., LTD.Inventors: Kwang Ok Lee, Kyung Hwa Lee, Eun Ju Jeong
-
Publication number: 20210284658Abstract: The present invention provides a novel thiazole derivative or a pharmaceutically acceptable salt thereof, and a method for preparing the same. The thiazole derivative or pharmaceutically acceptable salt thereof according to the present invention has selective inhibitory activity against cyclin-dependent kinase (CDK) and thus can be used as a preventive or therapeutic agent for various diseases associated with CDK.Type: ApplicationFiled: September 11, 2019Publication date: September 16, 2021Inventors: Kwang Ok Lee, Jakyung Yoo, Jun Flee Lee, Mijung Lee, Kangwoo Lee
-
Publication number: 20210061772Abstract: The present disclosure relates to a method for preparing tolimidone on large scale with maintaining high purity and uniform particle size distribution, and more specifically, a method suitable for preparing tolimidone on industrially large scale by using tetrabutyl ammonium bromide catalyst and recrystallization in ethanol, which can prepare highly pure tolimidone in a time shorter than prior arts while maintaining water content and particle size distribution constantly.Type: ApplicationFiled: January 11, 2018Publication date: March 4, 2021Inventors: Kwang Ok LEE, Kyung Hwa LEE, Eun Ju JEONG
-
Publication number: 20160229868Abstract: A novel fused pyrimidine derivative has an inhibitory activity for tyrosine kinases. A pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases contains the fused pyrimidine derivative as an active ingredient.Type: ApplicationFiled: April 15, 2016Publication date: August 11, 2016Applicant: HANMI SCIENCE CO., LTDInventors: Mi Young CHA, Seok Jong KANG, Mi Ra KIM, Ju Yeon LEE, Ji Young JEON, Myoung Gi JO, Eun Joo KWAK, Kwang Ok LEE, Tae Hee HA, Kwee Hyun SUH, Maeng Sup KIM
-
Patent number: 9345719Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.Type: GrantFiled: October 23, 2014Date of Patent: May 24, 2016Assignee: Hanmi Science Co., Ltd.Inventors: Mi Young Cha, Seok Jong Kang, Mi Ra Kim, Ju Yeon Lee, Ji Young Jeon, Myoung Gi Jo, Eun Joo Kwak, Kwang Ok Lee, Tae Hee Ha, Kwee Hyun Suh, Maeng Sup Kim
-
Patent number: 8957065Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.Type: GrantFiled: June 20, 2011Date of Patent: February 17, 2015Assignee: Hanmi Science Co., LtdInventors: Mi Young Cha, Seok Jong Kang, Mi Ra Kim, Ju Yeon Lee, Ji Young Jeon, Myoung Gi Jo, Eun Joo Kwak, Kwang Ok Lee, Tae Hee Ha, Kwee Hyun Suh, Maeng Sup Kim
-
Publication number: 20150045324Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.Type: ApplicationFiled: October 23, 2014Publication date: February 12, 2015Applicant: HANMI SCIENCE CO., LTDInventors: Mi Young CHA, Seok Jong KANG, Mi Ra KIM, Ju Yeon LEE, Ji Young JEON, Myoung Gi JO, Eun Joo KWAK, Kwang Ok LEE, Tae Hee HA, Kwee Hyun SUH, Maeng Sup KIM
-
Publication number: 20130116213Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.Type: ApplicationFiled: June 20, 2011Publication date: May 9, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Mi Young Cha, Seok Jong Kang, Mi Ra Kim, Ju Yeon Lee, Ji Young Jeon, Myoung Gi Jo, Eun Joo Kwak, Kwang Ok Lee, Tae Hee Ha, Kwee Hyun Suh, Maeng Sup Kim
-
Patent number: 8188102Abstract: The present invention provides a novel amide derivative of formula (I) and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same as an active ingredient.Type: GrantFiled: June 5, 2008Date of Patent: May 29, 2012Assignee: Hanmi Holdings Co., Ltd.Inventors: Kwang-Ok Lee, Mi Young Cha, Mi Ra Kim, Young Hee Jung, Chang Gon Lee, Se Young Kim, Keukchan Bang, Bum Woo Park, Bo Im Choi, Yun Jung Chae, Mi Young Ko, Han Kyong Kim, Young-Gil Ahn, Maeng Sup Kim, Gwan Sun Lee
-
Publication number: 20100179120Abstract: The present invention provides a novel amide derivative and a pharmaceutically acceptable salt thereof which selectively and effectively inhibits the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor and also prevents the development of drug resistance caused by the mutation of EGFR tyrosine kinase, and a pharmaceutical composition comprising same as an active ingredient.Type: ApplicationFiled: June 5, 2008Publication date: July 15, 2010Applicant: HANMI PHARM. CO., LTD.Inventors: Kwang-Ok Lee, Mi Young Cha, Mi Ra Kim, Young Hee Jung, Chang Gon Lee, Se Young Kim, Keukchan Bang, Bum Woo Park, Bo Im Choi, Yun Jung Chae, Mi Young Ko, Han Kyong Kim, Young-Gil Ahn, Maeng Sup Kim, Gwan Sun Lee
-
Publication number: 20020061919Abstract: Pure 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a pharmaceutically acceptable salt thereof is prepared in a high yield by a simple process which reacts 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one with a 2-methylimidazole derivative in an organic solvent or in a mixture of an organic solvent and water in the presence of a halosilane compound.Type: ApplicationFiled: November 20, 2001Publication date: May 23, 2002Inventors: Kwang-Ok Lee, Hee-Seock Kim, Young-Jin Ham, Maeng-Sup Kim, Han-Kyeng Kim, Cheol-Kyeung Kim, Kum-Sin Jung, Hoe-Chul Lee, Ki-Eun Kim, Gwan-Sun Lee
-
Patent number: 6388091Abstract: Pure -1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a pharmaceutically acceptable salt thereof is prepared in a high yield by a simple process which reacts 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one with a 2-methylimidazole derivative in an organic solvent or in a mixture of an organic solvent and water in the presence of a halosilane compound.Type: GrantFiled: November 20, 2001Date of Patent: May 14, 2002Assignee: Hanmi Pharm. Co., Ltd.Inventors: Kwang-Ok Lee, Hee-Seock Kim, Young-Jin Ham, Maeng-Sup Kim, Han-Kyeng Kim, Cheol-Kyeung Kim, Kum-Sin Jung, Hoe-Chul Lee, Ki-Eun Kim, Gwan-Sun Lee
-
Patent number: 6130336Abstract: The present invention elates to a process for preparing paclitaxel represented by formula (1) characterized in that: (a) an oxazolidine derivative represented by formula (2) or its salt in which X represents halogen, is coupled with a 7-trihaloacetyl-baccatin III represented by formula (3) in which R.sub.1 represents trihaloacetyl, in a solvent in the presence of a condensing agent to produce an oxazolidine substituent-containing taxane represented by formula (4) in which X and R.sub.1 are each as previously defined; (b) the oxazolidine ring is opened in a solvent in the presence of an acid, and the product thus obtained is reacted with benzoyl chloride in the presence of a base to produce a protected paclitaxel wherein the hydroxy group at 7-position is protected with trihaloacetyl group represented by formula (5) in which R.sub.1 is as previously defined; (c) then the protecting group at 7-position is removed by ammonia or a salt of ammonia with a weak acid in a solvent.Type: GrantFiled: February 23, 1999Date of Patent: October 10, 2000Assignee: Hanmi Pharm., Co. Ltd.Inventors: Kyoung Soo Kim, Ki Byung Chai, Young Ho Moon, Kwang Ok Lee, Nam Du Kim, Tae Hee Ha, Jung Ae Shin, Gwan Sun Lee, Wan Joo Kim
-
Patent number: RE46511Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.Type: GrantFiled: April 14, 2016Date of Patent: August 15, 2017Assignee: HANMI SCIENCE CO., LTD.Inventors: Mi Young Cha, Seok Jong Kang, Mi Ra Kim, Ju Yeon Lee, Ji Young Jeon, Myoung Gi Jo, Eun Joo Kwak, Kwang Ok Lee, Tae Hee Ha, Kwee Hyun Suh, Maeng Sup Kim